基本信息
浏览量:266
职业迁徙
个人简介
Dr. Melinda Telli is an Associate Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of ‘beyond BRCA’ DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.
研究兴趣
论文共 254 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Julia Ransohoff, Iain Miller, Jocelym Koo, Vishal Joshi,Allison Kurian,Kimberly Allison,Esther John,Melinda Telli
Cancer Researchno. 9_Supplement (2024): PS18-10
Fatima Cardoso, Joyce O'Shaughnessy,Heather McArthur,Peter Schmid,Javier Cortes, Nadia Harheck,Melinda L. Telli,David W. Cescon,Peter A. Fasching,Zhimin Shao,Delphine Loirat,Yeon Hee Park,
ANNALS OF SURGICAL ONCOLOGYno. 1 (2024): S4-S5
引用0浏览0引用
0
0
Humaira Noor,Yuanning Zheng,Adam Mantz, Ryle Zhou,Andrew Kozlov,Wendy B. DeMartini,Shu-tian Chen,Satoko Okamoto,Debra Ikeda,Sarah Mattonen,Sandy Napel,Melinda L. Telli,
Cancer Researchno. 6_Supplement (2024): 3510-3510
Julia D. Ransohoff, Iain Miller,Jocelyn Koo, Vishal Joshi,Allison W. Kurian,Kimberly H. Allison,Esther M. John,Melinda L. Telli
JNCI CANCER SPECTRUMno. 2 (2024)
STEM CELL RESEARCH (2023): 103246-103246
Stem cell research (2023): 103219-103219
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn